Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zeprumetostat + Glofitamab + GemOx in R/R DLBCL
NCT07643805Phase 2Not yet recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Jun 2026
- Primary completion
- Jan 2028
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of zeprumetostat in diffuse large B-cell lymphoma (DLBCL), sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: Complete Response Rate at 12 months. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
zeprumetostat
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT07643805.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07643805.